124 related articles for article (PubMed ID: 21083246)
21. Experiences with learning and confirming in drug and biological development.
Patterson SD
Clin Pharmacol Ther; 2010 Aug; 88(2):161-3. PubMed ID: 20648033
[TBL] [Abstract][Full Text] [Related]
22. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
Korfmacher W
Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
[No Abstract] [Full Text] [Related]
23. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
24. Microdosing: the new pharmacokinetic paradigm?
Zanni GR; Wick JY
Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
[TBL] [Abstract][Full Text] [Related]
25. Utilization of DBS within drug discovery: development of a serial microsampling pharmacokinetic study in mice.
Clark GT; Haynes JJ; Bayliss MA; Burrows L
Bioanalysis; 2010 Aug; 2(8):1477-88. PubMed ID: 21083348
[TBL] [Abstract][Full Text] [Related]
26. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.
Bauer M; Langer O; Dal-Bianco P; Karch R; Brunner M; Abrahim A; Lanzenberger R; Hofmann A; Joukhadar C; Carminati P; Ghirardi O; Piovesan P; Forloni G; Corrado ME; Lods N; Dudczak R; Auff E; Kletter K; Müller M
Clin Pharmacol Ther; 2006 Sep; 80(3):216-27. PubMed ID: 16952488
[TBL] [Abstract][Full Text] [Related]
27. Microdosing and drug development: past, present and future.
Lappin G; Noveck R; Burt T
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
[TBL] [Abstract][Full Text] [Related]
28. Interview: Interview with Professor Malcolm Rowland.
Rowland M
Bioanalysis; 2010 Mar; 2(3):385-91. PubMed ID: 21083248
[TBL] [Abstract][Full Text] [Related]
29. Mass spectrometry imaging in drug development.
Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
[No Abstract] [Full Text] [Related]
30. Human microdosing for the prediction of patient response.
Henderson PT; Pan CX
Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245
[No Abstract] [Full Text] [Related]
31. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
32. Antibiotic discovery in the twenty-first century: current trends and future perspectives.
Donadio S; Maffioli S; Monciardini P; Sosio M; Jabes D
J Antibiot (Tokyo); 2010 Aug; 63(8):423-30. PubMed ID: 20551985
[TBL] [Abstract][Full Text] [Related]
33. Impact of NEDO project on microdosing clinical studies: toward the eIND study in Japan.
Yamashita S
Drug Metab Pharmacokinet; 2011; 26(6):549-50. PubMed ID: 22214558
[No Abstract] [Full Text] [Related]
34. Next-generation model-based drug discovery and development: quantitative and systems pharmacology.
Allerheiligen SR
Clin Pharmacol Ther; 2010 Jul; 88(1):135-7. PubMed ID: 20531467
[TBL] [Abstract][Full Text] [Related]
35. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
36. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
Tolonen A; Turpeinen M; Pelkonen O
Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
[TBL] [Abstract][Full Text] [Related]
37. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
38. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
39. Development of anti-cancer drugs.
Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
[TBL] [Abstract][Full Text] [Related]
40. The importance of drug-target residence time.
Zhang R; Monsma F
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
